Correction of a release from 22.01.2018, 16:33 CET/CEST - Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
January 23, 2018 at 08:15 am EST
Share
DGAP Voting Rights Announcement: Epigenomics AG
Correction of a release from 22.01.2018, 16:33 CET/CEST - Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
23.01.2018 / 14:13
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
2. Reason for notification
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
X
Other reason: Voluntary Notification / Restructuring of group shareholdings in Epigenomics
3. Details of person subject to the notification obligation
Name:
City and country of registered office:
Biochain Institute, Inc.
Newark, CA 94560 United States of America (USA)
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
5. Date on which threshold was crossed or reached:
05 Jan 2018
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
total of both in % (7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation
4.67 %
%
4.67 %
24014360
Previous notification
4.67 %
%
4.67 %
/
7. Notified details of the resulting situation a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN
absolute
in %
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
DE000A11QW50
1120685
4.67 %
%
Total
1120685
4.67 %
b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
%
Total
%
b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
%
Total
%
8. Information in relation to the person subject to the notification obligation
X
Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least held 3% or more)
% of voting rights through instruments (if at least held 5% or more)
Total of both (if at least held 5% or more)
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
Date of general meeting:
Holding position after general meeting:
% (equals voting rights)
10. Other explanatory remarks:
Globetrotter(BVI) Holdings, Ltd. as well as the group companies controlling Biochain Institute, Inc. were dissolved with effect as of 5 January 2018. 1,120,685 shares in Epigenomics were acquired by Biochain
Institute, Inc. as a result of Globetrotter(BVI)Holdings,Ltd. being dissolved.
23.01.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
EPIGENOMICS AG 
